EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (soluble LAG-3) & Pembrolizumab in 2nd Line PD-1/PD-L1 Refractory Metastatic NSCLC

Eftilagimod alpha (efti) is a soluble LAG-3 protein binding to a subset of MHC class II molecules to mediate antigen presenting cell (APC) and CD8 T-cell activation. Stimulating APCs and subsequent T cell recruitment with efti may revert PD-1 resistance. We hereby report updated results from part B of the TACTI-002 trial: 2nd line PD-1/PD-L1 refractory non-small cell lung carcinoma (NSCLC) pts treated with efti plus pembrolizumab.